PALISADE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 0.00 shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 0.00 shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 0.00 shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 0.00 shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- PALISADE BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-03-20 | |
| 2024-12-31 | 0.00 shares 10-K · filed 2025-03-24 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 0.00 shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 0.00 shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 0.00 shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | 0.00 shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | 0.00 shares 10-K · filed 2023-03-22 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 0.00 shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 0.00 shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-13 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 0.00 shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-09 | 1.02M shares derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 1.03M shares 10-K · filed 2016-03-14 |
| 2015-09-30 | 998.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | 1.03M shares derived: sum of 4 quarters · filed 2015-11-09 |
| 2015-06-30 | 23.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | 35.51K shares derived: sum of 4 quarters · filed 2015-08-10 |
| 2015-03-31 | 9.94K shares 10-Q · filed 2015-05-08 | 28.36K shares derived: sum of 4 quarters · filed 2015-05-08 |
| 2014-12-31 | 287.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | 322.52K shares 10-K · filed 2015-03-16 |
| 2014-09-30 | 2.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | 322.23K shares derived: sum of 4 quarters · filed 2014-11-07 |
| 2014-06-30 | 15.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | 320.06K shares derived: sum of 4 quarters · filed 2014-08-08 |
| 2014-03-31 | 304.10K shares 10-Q · filed 2014-05-12 | 304.10K shares derived: sum of 4 quarters · filed 2014-05-12 |
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | 0.00 shares 10-K · filed 2014-03-10 |
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | 0.00 shares derived: sum of 4 quarters · filed 2013-11-12 |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | 0.00 shares derived: sum of 4 quarters · filed 2013-08-08 |
| 2013-03-31 | 0.00 shares 10-Q · filed 2013-05-10 | |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | 0.00 shares 10-K · filed 2013-03-15 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | |
| 2011-12-31 | 0.00 shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |